Navin Molecular, an Indian-headquartered CDMO with small molecule development and manufacturing capabilities, recently announced a Rs 288 Crore (approximately €32.6 million/$35 million) investment to construct a 9,000 m2 GMP manufacturing plant in Dewas, India. The new facility will nearly double the overall capacity at the site to 420 m3. It will support existing commercial-scale projects and meet future demands as the company continues to expand its global customer base.